A new research document with title ‘Pain Drug Development Pipeline Review, 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors. The report will help user gain market insights, future trends and growth prospects for forecast.
Request a sample report @ https://www.htfmarketreport.com/sample-report/560278-pain-drug-development-pipeline-review
Pain Drug Development Pipeline Review, 2017
This report provides an overview of the pain pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Osteoarthritis Pain, Migraine pain and Neuropathic Pain, therefore covering a number of the most difficult-to-treat chronic and acute pain subtypes.
Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Finally neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury, in which the nerve fibres could be damaged resulting in the generation of abnormal signals. However, it is exhibited in a range of diseases and has no specific identifiable cause.
The size of these pipelines ranges from 62 products in osteoarthritis pain to 249 in neuropathic pain. Within osteoarthritis pain, prostaglandin G/H synthases 1 and 2 and the nerve growth factor receptors are being studied by the most pipeline products; while the prostaglandin receptors are frequently targeted by already approved marketed products, the nerve growth factor receptors are not.
In migraine, it is the 5-hydroxytryptamine (serotonin) receptors 1D and 1B which are being most frequently studied, again reflecting the composition of the market for this indication. However, the calcitonin gene related peptide and its receptor, also very frequently targeted, are not yet present in the migraine market. Finally, the favoured targets of neuropathic pain are the sodium channel protein type 9 (Nav1.9) and the mu type opioid receptor. While the latter is already heavily targeted in the pain market, the former is not.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=560278
– Which companies are the most active within the pipeline for pain therapeutics?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in the field of pain therapeutics?
Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/560278-pain-drug-development-pipeline-review
Table of Contents
Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 5
List of Figures 11
Research Report Coverage 12
Osteoarthritis Pain – Overview 12
Migraine – Overview 12
Neuropathic Pain – Overview 12
Therapeutics Development 13
Osteoarthritis Pain 13
Neuropathic Pain 28
Therapeutics Assessment 45
Osteoarthritis Pain 45
Neuropathic Pain 65
Companies Involved in Therapeutics Development 78
Osteoarthritis Pain 78
Neuropathic Pain 117
Dormant Projects 177
Osteoarthritis Pain 177
Neuropathic Pain 182
Discontinued Products 191
Osteoarthritis Pain 191
Neuropathic Pain 193
Product Development Milestones 196
Osteoarthritis Pain 196
Neuropathic Pain 217
Secondary Research 228
Primary Research 228
Expert Panel Validation 228
Contact Us 228
Disclaimer 229List of Tables
Number of Products under Development for Osteoarthritis Pain 13
Number of Products under Development by Companies, Osteoarthritis Pain 15
Number of Products under Development by Universities/Institutes, Osteoarthritis Pain 17
Products under Development by Companies, Osteoarthritis Pain 18
Products under Development by Universities/Institutes, Osteoarthritis Pain 19
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/560278-pain-drug-development-pipeline-review
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218